CT:IQ is delighted to welcome Pharmaceutical Product Development (PPD) to the Steering Committe.
PPD, part of Thermo Fisher Scientific, is a leading global contract research organisation (CRO) focused on delivering life-changing therapies. PPD provides comprehensive lab services, integrated drug development, clinical trial therapeutic expertise and lifecycle management services.
In December 2021, PPD became a wholly owned subsidiary of Thermo Fisher Scientific. PPD is now Thermo Fisher’s Clinical Research Group.
PPDs broad range of clinical development and analytical services creates custom-tailored solutions for their customers in pharma, biotech, medical device, and government organisations. PPD is committed to making operational excellence an asset for development programs worldwide.
CT:IQ looks forward to working with PPD on future clinical trials improvement projects.
